Risks, Benefits in Policy Changes for Developing Rare Disease Treatments
The potential risks and benefits of several policy changes that could affect the landscape of developing treatments for rare diseases like Lambert-Eaton myasthenic syndrome (LEMS) were discussed in a recent white paper. The paper, “The Next Generation of Rare Disease Drug Policy: Ensuring Both Innovation and Affordability,” was…